Kevin Flanigan, MD
Nationwide Children's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kevin Flanigan, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:28 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06096441 · FSHD Molecular CharacterizationNationwide Children's Hospital · terminated · Facio-Scapulo-Humeral Dystrophy · principal investigator
- Ph2NCT04179409 · A 48-Week, Open Label, Study to Evaluate the Efficacy and Safety of AMONDYS 45, EXONDYS 51, VYONDYS 53 in Subjects With DuchenneMuscular Dystrophy Carrying Eligible DMD Duplications.Kevin Flanigan · completed · Duchenne Muscular Dystrophy · principal investigator
- Ph1NCT03777319 · Spironolactone Versus Prednisolone in DMDKevin Flanigan · terminated · Muscular Dystrophy, Duchenne · principal investigator
- Ph1/Ph2NCT03333590 · Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular DystrophyKevin Flanigan · completed · Duchenne Muscular Dystrophy · principal investigator
- Ph1/Ph2NCT02704325 · Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2Kevin Flanigan · withdrawn · Duchenne Muscular Dystrophy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.